Analytical Data
-
Gene name
DNASEIIb
- Application
-
Alternative Names
DNase-IIb; DNase2b; DNase2-b; DLAD; DNASE2-Like Acid DNase; Endonuclease DLAD
-
Species
Rat
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9QZK9
-
Expression Region
Thr23~Asn356
-
Molecular Weight
68kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DNase IIb is a member of the DNase family of enzymes, primarily involved in the degradation of extracellular DNA, which plays a crucial role in various physiological processes, including tissue remodeling and the immune response. Its function is particularly significant in the context of inflammation, as the clearance of extracellular DNA released from dying cells is essential for preventing autoimmunity and maintaining tissue homeostasis. Moreover, recent studies have unveiled the potential role of DNase IIb in cancer biology, where aberrant extracellular DNA signaling may influence tumor progression and the tumor microenvironment. The recombinant form of DNase IIb is increasingly being explored for its therapeutic potential in treating diseases characterized by excessive extracellular DNA, such as autoimmune disorders and cancer. Understanding the structural and functional properties of recombinant DNase IIb is vital for developing targeted therapies and optimizing its application in clinical settings. Thus, ongoing research aims to elucidate its biochemical mechanisms, regulatory pathways, and interactions with other cellular components, paving the way for novel therapeutic strategies harnessing the biological activities of DNase IIb.
